Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Gerold Bepler, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator - John C Ruckdeschel, MD
Barbara Ann Karmanos Cancer Institute
Principal Investigator - Peter D Eisenberg, MD
California Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- California Cancer Center
Greenbrae, California, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- Karmanos Cancer Institute
Detroit, Michigan, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2007
- Primary completion
- 30 Nov 2007
- Completion
- 30 Nov 2007
- Last update posted
- 30 Apr 2009
- Registered enrollment
- 50
- Registry id
- NCT00435578
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.